AlphAIAlphAI — Financial news for AI agents
rttnews.comOCT 152 min read$CLRB

Cellectar Biosciences Eyes 2027 FDA Filing For Iopofosine In Waldenström Patients

Cellectar Biosciences (CLRB) reported positive Phase 2b trial results for iopofosine I 131 in Waldenström macroglobulinemia patients, with 87.5% overall response rate. The company plans a Phase 3 trial and FDA filing in 2027. Shares fell 15.11% on the news.

Original reporting
rttnews.com
Published Oct 15, 2026, 12:31 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 15, 2026, 12:38 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefTechnology
Primary signal
$CLRB
Bearish
high confidence
Mentioned
$CLRB
Relevance
8/10
AlphAI data visualization · based on rttnews.com
Decision brief

The 30-second read

$CLRBBearishMed
01

Why it matters

The disclosed subgroup data provide the first efficacy signal for the program, prompting a sharp sell‑off as investors reassess risk versus reward.

02

Market read

First‑time trial data release for a micro‑cap biotech, driving immediate price movement and setting the stage for future FDA filing expectations.

03

What to watch

Potential competitive advantage of the PDC platform and upcoming FDA filing timeline may attract long‑term investors.

Relevance 8/10Novelty 8/10Timing: pre‑market today

Background

Cellectar Biosciences (CLRB) is developing iopofosine I‑131, a targeted radiopharmaceutical for Waldenström macroglobulinemia, and plans an FDA submission in early 2027.

Company-level read

Ticker impact

$CLRBBearishHigh confidence
Context

Cellectar Biosciences announced positive Phase 2b subgroup efficacy data for iopofosine I‑131, causing a 15.11% share decline.

Expected impact

likely downside as the market prices in modest efficacy and the small sample size

Evidence & confidence

First disclosure of trial results, shares already fell 15%; no further catalyst announced, so short‑term bias remains negative.

Market effects

Sector

Biotech sector may see heightened scrutiny of early‑stage radiopharmaceutical programs.

Regional

U.S. biotech investors could adjust exposure to small‑cap oncology pipelines.

Global

Limited; impact confined to niche cancer‑therapy investors.

Counterpoint

What could challenge this read

The high response rates could signal a breakthrough, offering upside if Phase 3 confirms efficacy.

Key entities

  • company
    Cellectar Biosciences

    Developer of iopofosine I‑131 radiopharmaceutical.

  • event
    International Workshop for Waldenström Macroglobulinemia

    Venue where the trial data were presented.

Read at source← All news

Related articles

OCT 27
$CLRBMedAI 8/10

Cellectar Reports 8-Year Complete Response With Iopofosine I 131; Stock Up

Cellectar Biosciences (CLRB) reported a case study where Iopofosine I 131 achieved an 8-year complete response in a DLBCL patient. The treatment led to full resolution of the targeted lesion. CLRB is advancing the drug for another blood cancer and expects to start a Phase 3 study in Q1 2027. The stock was up 5.79% in pre-market trading.

rttnews.com1 min
OCT 27
$CLRBMedAI 9/10

Cellectar reports 8-year remission in lymphoma case study

Cellectar Biosciences (CLRB) reported an 8-year remission in a lymphoma patient treated with iopofosine I 131. The patient achieved complete response by day 85 and has shown no disease progression since. The company plans to submit findings for publication and is advancing a Phase 3 study in Waldenström macroglobulinemia, with FDA submission expected in 2027. Iopofosine I 131 has received several FDA designations for various cancer indications.

investing.com2 min
AUG 22
$CLRBMedAI 8/10

Cellectar Biosciences Earnings Call Highlights Clinical Momentum - TipRanks.com

Cellectar Biosciences (CLRB) reported Q2 earnings, highlighting strong clinical data for iopofosine and a clear regulatory path. The CLOVER-WaM study showed high response rates in Waldenstrom’s macroglobulinemia. The company plans a Phase III trial and accelerated approval submission in 2027. Financing of up to $140M was secured, improving cash position to $34M. R&D expenses increased, widening net loss to $6.9M. Management acknowledged dilution risks and operational challenges.

tipranks.com3 min
AUG 17
$CLRBMed

Cellectar Biosciences Inc (CLRB) (Q2 2026) Earnings Call Highlights: Strong Clinical Data

Cellectar Biosciences (CLRB) reported Q2 2026 results on an earnings call, including $34.0M cash at June 30, 2026, $4.6M R&D expense, and a $6.9M net loss ($0.57/share). Management discussed Phase 3 WM site activation, targeted accelerated-approval submission in March-April 2027, CLR 125 data later in 2026/early 2027, and actinium-225 multi-sourcing. The May financing added $35M upfront plus milestone warrants up to $105M.

yahoo.com7 min
AUG 13
$CLRBMed

Cellectar Reports Q2 2026 Results, Strengthened Cash Positions Supports Oncology Pipeline

Cellectar Biosciences (CLRB) reported Q2 2026 results. Cash and cash equivalents were $34.0M as of June 30, 2026, funding operations into Q2 2027. R&D rose to $4.6M from $2.4M a year earlier; net loss was $6.9M, or $0.57/share. Pipeline progress includes Phase 3 prep for Iopofosine I 131 in Waldenström macroglobulinemia and Phase 1b enrollment for CLR 125 in triple-negative breast cancer.

rttnews.com5 min